Clinical response to bevacizumab in schwannomatosis
نویسندگان
چکیده
منابع مشابه
Bevacizumab in clinical practice.
The development of targeted therapies and especially angiogenesis inhibitor drugs is undoubtedly a major advancement in the treatment of cancer in the 21st century. Bevacizumab is a recombinant humanized monoclonal antibody directed against vascular endothelial growth factor that was approved for the treatment of multiple solid tumors, we have reviewed the side effects cited in clinical trials ...
متن کاملPatient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials.
OBJECTIVES Neurofibromatosis (NF) is a genetic disease with multiple clinical manifestations that can significantly impact quality of life (QOL). Clinical trials should include patient-reported outcomes (PROs) as endpoints to assess treatment effects on various aspects of QOL, but there is no consensus on the selection and use of such measures in NF. This article describes the PRO Working Group...
متن کاملBiomarkers and response to bevacizumab--letter.
We read with interest the proteomic study by Collinson and colleagues (1), proposing a biomarker signature with promising ability in predicting benefit from the addition of bevacizumab to standard chemotherapy in epithelial ovarian cancer (EOC). The identification of predictors of benefit from bevacizumab is one of the most pressing priority in medical oncology, as indications for its use have ...
متن کاملRapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis
Recurrent respiratory papillomatosis (RRP) is a primary benign disease, which is characterized by papillomatous growth in the respiratory tract. Malignant transformation occurs in only 3-5% of cases, however, local growth of the benign papillomas is interpreted as clinically malignant in a markedly higher proportion of patients. Local surgical or endoscopic interventional debulking or excision ...
متن کاملDramatic response to panitumumab and bevacizumab in metastatic gallbladder carcinoma.
Disclosures: Elizabeth Riley: None; Harry Carloss: Honoraria: Amgen; Research funding/contracted research: Amgen. This letter contains information on the unlabeled use of panitumumab and bevacizumab. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the conte...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurology
سال: 2014
ISSN: 0028-3878,1526-632X
DOI: 10.1212/wnl.0000000000000997